CIK 0001287098
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
MAXCYTE, INC.
Sign in to watch- Ticker
- MXCT
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 522210438
- Phone
- +1 301-517-5556
- Business address
- 9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, MD, 20850
- Former names
- MAXCYTE INC
- 4 Grant or award Director acquired 21,367 shares (grant or award)
- 4 Open-market buy President and CEO bought 100,000 shares at an average $4.89 ($489,066)
- 4 Planned sale Director sold 5,000 shares at $4.41 ($22,025)
- 4 Grant or award EVP, GLOBAL SALES & MARKETING acquired 25,000 shares (grant or award)
- 4 Grant or award GENERAL COUNSEL acquired 3,913 shares (grant or award)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 81,250 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Director sold 5,000 shares at $4.60 ($23,005)
- 4 Planned sale Director sold 5,000 shares at $5.12 ($25,585)
- 4 Derivatives Options or other derivatives
- 4 Planned sale Director sold 5,000 shares at $4.53 ($22,650)
- 4 Open-market sale President and CEO sold 124,450 shares at an average $5.14 ($639,405)
- 4 Open-market sale President and CEO sold 25,550 shares at $5.00 ($127,750)
- 4 Planned sale Director sold 5,000 shares at $4.59 ($22,950)
- 4 Planned sale Director sold 10,000 shares at $3.71 ($37,100)
- 4 Planned sale Director sold 5,000 shares at $3.70 ($18,500)
- 4 Planned sale Director sold 5,000 shares at $4.75 ($23,750)
- 4 Planned sale President and CEO sold 30,000 shares at an average $5.03 ($150,852)
- 4 Planned sale Director sold 15,000 shares at an average $4.44 ($66,603)
- 4 Derivatives Options or other derivatives
Page 4 of 9 · 163 filings